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Genetic variants associated with asthma pathogenesis and altered response to drug
therapy are discussed. Many studies implicate polymorphisms in genes encoding
the enzymes responsible for leukotriene synthesis and intracellular signaling through
activation of seven transmembrane domain receptors, such as the cysteinyl leukotriene
1 (CYSLTR1) and 2 (CYSLTR2) receptors. The leukotrienes are polyunsaturated
lipoxygenated eicosatetraenoic acids that exhibit a wide range of pharmacological
and physiological actions. Of the three enzymes involved in the formation of the
leukotrienes, arachidonate 5 lipoxygenase 5 (ALOX5), leukotriene C4 synthase (LTC4S),
and leukotriene hydrolase (LTA4H) are all polymorphic. These polymorphisms often
result in variable production of the CysLTs (LTC4, LTD4, and LTE4) and LTB4.
Variable number tandem repeat sequences located in the Sp1-binding motif within
the promotor region of the ALOX5 gene are associated with leukotriene burden and
bronchoconstriction independent of asthma risk. A 444A > C SNP polymorphism
in the LTC4S gene, encoding an enzyme required for the formation of a glutathione
adduct at the C-6 position of the arachidonic acid backbone, is associated with severe
asthma and altered response to the CYSLTR1 receptor antagonist zafirlukast. Genetic
variability in the CysLT pathway may contribute additively or synergistically to altered
drug responses. The 601 A > G variant of the CYSLTR2 gene, encoding the Met201Val
CYSLTR2 receptor variant, is associated with atopic asthma in the general European
population, where it is present at a frequency of ∼2.6%. The variant was originally found
in the founder population of Tristan da Cunha, a remote island in the South Atlantic, in
which the prevalence of atopy is approximately 45% and the prevalence of asthma is
36%. In vitro work showed that the atopy-associated Met201Val variant was inactivating
with respect to ligand binding, Ca2+ flux and inositol phosphate generation. In addition,
the CYSLTR1 gene, located at Xq13-21.1, has been associated with atopic asthma. The
Frontiers in Pharmacology | www.frontiersin.org 1 December 2016 | Volume 7 | Article 299
fphar-07-00299 December 5, 2016 Time: 16:49 # 2
Thompson et al. Asthma on Tristan da Cunha and Beyond
activating Gly300Ser CYSLTR1 variant is discussed. In addition to genetic loci, risk for
asthma may be influenced by environmental factors such as smoking. The contribution
of CysLT pathway gene sequence variants to atopic asthma is discussed in the context
of other genes and environmental influences known to influence asthma.
Keywords: montelukast, pharmacogenetics, pharmacogenomics, cysteinyl leukotriene 1 (CYSLTR1), cysteinyl
leukotriene 2 (CYSLTR2), epistasis, epigenetics, Tristan da Cunha
INTRODUCTION
Given that the prevalence of asthma may be increasing in
many populations world-wide (Eder et al., 2006), it is significant
that advances in treatment may result from an improved
understanding of both the molecular basis of asthma and its
responsiveness to therapy. Both asthma susceptibility loci, the
genetic variability that confers risk for complex respiratory traits
that lead to asthma, and pharmacogenetics, the genetic variability
that confers responsiveness of an individual to pharmaceutical
therapy, may be best modeled as independent complex traits
with both genetic and environmental (GXE) contributions. Since
variability in the genes encoding the proteins essential for
inflammation may influence risk for many aspects of asthmatic
inflammation (Drazen et al., 2000), it is to be expected that it
might also increase the susceptibility to asthma independent of
their pharmacogenetic relevance (Thompson et al., 2008). Here,
we discuss the relative contribution of genes in the cysteinyl
leukotriene (CysLT) pathway to both the etiology of asthma itself
and a person’s responsiveness to leukotriene modifying (LTM)
drugs.
While in some cases the genetic variants that result in disease
also encode protein targets for pharmaceutical interventions, this
relationship is often not consistent even with polymorphisms
of a G protein-coupled receptor (GPCR) system such as the
one that mediates CysLT inflammation. For example, while
variability in the genes encoding drug targets such as the cysteinyl
leukotriene 1 (CYSLTR1) and 2 (CYSLTR2) receptor genes may
both contribute to risk for atopic asthma in some populations
(Thompson et al., 2003, 2005b, 2013; Pillai et al., 2004; Brochu-
Bourque et al., 2011; Yaddaden et al., 2016), only the cysteinyl
leukotriene 1 (CYSLTR1) receptor is targeted by LTMs. We can
only speculate, however, on the role that that variability in the
cysteinyl leukotriene 2 (CYSLTR2) receptor may have in LTM
pharmacogenetics since drugs targeting the CYSLTR2 receptor
are not widely available.
In general, respiratory disease itself, and patient response
to therapy, may be best modeled as independent complex
traits with both genetic and environmental contributions. The
GPCR associated with asthma, the (NPSR1) neuropeptide S
receptor 1 (Laitinen et al., 2004; Kormann et al., 2005;
Melén et al., 2005; Pietras et al., 2011), may represent an
exception inasmuch as it also defines a potential therapeutic
target. As a result, many advances in pharmacogenetics have
resulted not from linkage or candidate gene studies but from
Genome Wide Association Studies (GWAS). Hence, the field
of pharmacogenomics has become axiomatic in the study of
patient response and non-response to medication, adverse drug
reactions, and optimizing drug dose for the individual.
FIGURE 1 | Cysteinyl leukotriene synthesis pathway. Leukotriene
biosynthesis inhibitors act on either 5-lipoxygenase or its activating protein
(FLAP). The class of cysteinyl leukotriene (CysLT) receptor antagonists target
the CysLT receptors CYSLTR1 and CYSLTR2. 5-HPETE, 5-hydroxyperoxy-
eiocosatetraenoic acid.
The study of CYSLTR1 and CYSLTR2 gene variability in
asthma, therefore, must be considered in the context of the
genetic polymorphisms found within the synthesis pathway genes
as well as genes that modify patient response to LTMs. The LTMs
used to treat asthma, such as montelukast, a drug which targets
cysteinyl leukotriene 1 (CYSLTR1) receptor protein, have a
greater than 20% non-response rate (Noonan et al., 1998). While
some of the pharmacogenetic determinants of LTM response
are attributable to variability in genes that are integral (Kang
et al., 2011; Mougey et al., 2013) to the signaling of cysteinyl
leukotrienes (Figure 1), many true pharmacogenetic variants are
located in genes that lie directly outside the pathway (Dahlin
et al., 2015, 2016).
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In order to undertake GWAS studies of complex traits,
a large sample size is generally required. Thus, informative
studies of the genetic basis of drug response are conducted
among large samples of unrelated individuals recruited from a
given population. This is especially true for asthma phenotypes
studied in out-bred populations since they tend to be genetically
heterogeneous (Moffatt et al., 2007; Michel et al., 2010; Sleiman
et al., 2010; Ferreira et al., 2011; Melén et al., 2013). By
contrast, small candidate gene studies have achieved reasonable
power for detecting variants that confer risk (Marshall et al.,
2013). Since data from sequencing large patient cohorts has
become available, it has been possible to assess the wider
relevance of some observations originally made in smaller
studies.
For example, our study of atopic asthma in the Tristan
da Cunha isolate provided early insight into CysLT
pharmacogenetics (Thompson et al., 2006; Capra et al., 2007;
Brochu-Bourque et al., 2011). In particular, the hypomorphic
Met201Val CYSLTR2 variant identified on Tristan da Cunha
(Thompson et al., 2003) has since been associated with atopy
in large out-bred populations (Pillai et al., 2004). Selected
examples of GPCR variants associated with asthma phenotypes
are presented in Table 1. Tables 2 and 3 present selected variants
of the CYSLTR1 and CYSLTR2 genes.
Population Isolates
Studies of population isolates rely upon the fact that a
founder effect limits genetic heterogeneity and results in greatly
increased prevalence rates (Roberts, 1968; Zamel et al., 1996).
In the Tristan da Cunha isolate, for example, there is a
45% prevalence of atopy and a 36% prevalence of asthma
(Mantle and Tyrrell, 1973; Zamel et al., 1996; Camacho
et al., 2011; Camacho and Cazelles, 2013). By comparison,
the prevalence of asthma in most out-bred populations rarely
exceeds 10%. The severity of the Tristan da Cunha atopy
phenotype may be reflected in events such as the Tristan da
Cunha influenza epidemic of 1971 (Mantle and Tyrrell, 1973;
Zamel et al., 1996; Camacho et al., 2011; Camacho and Cazelles,
2013).
Analyzing the transmission of genetic markers in a
large extended pedigree such as a population isolates,
provides the opportunity to identify risk alleles originating
from common ancestry (Soodyall et al., 1997, 2003).
In particular, this enrichment optimizes the analysis of
complex traits for gene-gene interaction effects. Even
though the asthma phenotype is relatively homogenous
on Tristan da Cunha, the fact that more than one of the
seven founders that populated the island after 1812 were
asthmatic (Levack and Levack, 2013) suggests that the
disorder manifested by the islanders is influenced by complex
inheritance.
The Tristan da Cunha findings (Thompson et al., 2003, 2007,
2013), therefore, must be interpreted not only in the context of a
founder effect (Zamel et al., 1996; Slutsky and Zamel, 1997; Chan-
Yeung et al., 1999) but also in the context of the many genes that
confer risk to asthma in out-bred populations: including GPCRs
variants (Table 1).
Out-Bred Populations
Genome Wide Association Studies have confirmed that variants
of the DENND1B gene, located on chromosome 1q31 (Sleiman
et al., 2010) and the ORMDL3 gene, located on chromosome
17q12 (Moffatt et al., 2007) underlie asthma pathogenesis in
many populations (Ferreira et al., 2011; Melén et al., 2013).
Other genes including ADAM33, CCL5, CD14, DPP10, EDN1,
NPSR1, GSTP1, IL12B, IL13, IL4, IL4R, PTGDR, TNF, and
VDR have also been found to be commonly associated with
asthma in various study populations (Michel et al., 2010).
Asthma resulting from certain genotypes has shown distinct
responses to drug treatment in some instances (Berce et al.,
2013). Differentiating the genetic basis of a heterogeneous disease
such as asthma, therefore, creates the opportunity to tailor
specific therapeutic regimens to the resulting endophenotype
(Rana et al., 2001; Milligan, 2002; Thompson et al., 2012,
2014a,c).
G protein-coupled receptors are the primary drug targets
for drug interventions into many forms of asthma. Many
advances in therapeutics have resulted from the identification of
GPCR variants that are associated with disease. Polymorphisms
of the β2-adrenergic receptor (ADRB2) gene may be among
the most clinically relevant with respect to drug response
(Thonkham et al., 2015). Like the subsequent study of
many GPCR variants, homology with the prototypical GPCR,
rhodopsin (Lefkowitz, 2004), was used to predict the functional
significance of sequence alterations. Many of these studies
were later evaluated in vitro (Rana et al., 2001; Lefkowitz,
2004).
Early studies showed that β2-adrenergic receptor variants
with altered pharmacological response are more common
in patients with asthma (Taylor and Kennedy, 2001, 2002;
Taylor et al., 2005; Hawkins et al., 2008) as well as congestive
heart failure (Thompson et al., 2014a). More recent studies
have linked polymorphisms of ADRB2 to altered drug
response (Basu et al., 2009; Mathias et al., 2010). Asthma
treatment with albuterol, which is targeted to ADRB2, is
often associated with increased hypersensitivity (Reihsaus
et al., 1993; Dewar et al., 1997; Liggett, 1997; Drysdale et al.,
2000; Israel et al., 2000; Littlejohn et al., 2002). Work is
currently underway to identify ADRB2 polymorphisms in
populations, such as the residents of Grenada, where 30%
of the children are reported to have asthma according to a
modified ISAAC survey (Pearce et al., 2007; Thonkham et al.,
2015).
Other candidate gene studies have identified GPCR gene
variants that are associated with asthma phenotypes from various
populations. In vivo and in vitro studies have determined
functional roles for many GPCR variants (Rana et al., 2001),
but evaluation of their physiological role in disease remains a
challenge (Thompson et al., 2014b). In addition to CYSLTR1
and CYSLTR2 receptor polymorphisms (Tables 2 and 3),
GPCR variants of significance to asthma pharmacogenetics are
presented in Table 1. These receptors include the endothelin-1
receptor type A (EDNRA; Mao et al., 1999; Michel et al., 2010),
prostaglandin D2 (PTGDR2; Cookson and Moffatt, 2004; Oguma
et al., 2004), thromboxane A2 (TBXA2R; Unoki et al., 2000;
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TABLE 1 | Human G-protein-coupled receptor (GPCR) variants associated with asthma endophenotype or altered pharmacology.
Receptor (gene name) Variant/allele Disease/phenotype Pharmacology Reference
Endothelin-1 receptor type
A (EDNRA)
Afi II Atopy; IgE levels increased Altered receptor expression Mao et al., 1999;
Michel et al., 2010
Beta2-adrenergic receptor
(ADRB2)
R16 > G Reduced lung function; nocturnal
asthma/severity
Downregulation enhanced;
albuterol response decreased
Hawkins et al., 2008;
Basu et al., 2009
Q27 > E Hypertension risk; obesity; IgE
levels increased
Downregulation resistant;
albuterol response increased;
drug hypersensitivity
Reihsaus et al., 1993;
Dewar et al., 1997;
Drysdale et al., 2000
G16/E27 haplotype Asthma, heart disease, immune
disorders
Drysdale et al., 2000
C341 > G None known Uncoupling from Gs/adenylyl
cyclase system
Lachance et al., 1999
Prostaglandin D2 receptor
(PTGDR)
Promoter SNPs undermine
normal helper T
anti-inflammatory response
Asthma Altered receptor expression
anti- immune response to
PGD2
Cookson and Moffatt,
2004; Oguma et al.,
2004
Chemoattractant receptor
on Th2 cells
(CRTH2/GPR44)
3′ UTR SNPs: 1651G > A,
1544C/1651A
Asthma Altered receptor expression;
inflammatory response to
PGD2
Hirai et al., 2001; Wang
et al., 2009
Thromboxane A2 receptor
(TBXA2R)
TP-alpha and TP-beta isoforms
SNPs
Asthma, atopy and
aspirin-intolerant asthma
Unoki et al., 2000; Kim
et al., 2005
Cysteinyl leukotriene
receptor 1 (CYSLTR1)
G300S Atopy Receptor activation Thompson et al., 2007;
Yaddaden et al., 2016
Cysteinyl leukotriene
receptor 2 (CYSLTR2)
M201V Various populations Receptor inactivation Thompson et al., 2003,
2005b; Pillai et al.,
2004; Brochu-Bourque
et al., 2011
Prostaglandin D2 receptor
(PTGDR)
-441T/C No disease association Montelukast response Kang et al., 2011
Chemokine [C-C motif]
receptor 5 (CCR5)
32 bp deletion; 59029 A > G Risk of asthma decreased Diminished CCR5 expression
on Th1 cells results in a
preponderance of Th2 cells;
decreased binding to activity;
decreased binding to CC
Hall et al., 1999;
Srivastava et al., 2003;
Agrawal and
Bharadwaj, 2005
G-protein-coupled receptor
associated with asthma
(GPRA or GPSR154)
GPRA-B isoform
over-expressed in bronchial
epithelia of asthmatics
Asthma Altered RANTES, MIP-1-alpha
ligand suggests that GPRA is a
potential drug target
Laitinen et al., 2004;
Kormann et al., 2005;
Melén et al., 2005;
Pietras et al., 2011
IgE, immunoglobulin E; MIP-1alpha, macrophage inhibitory protein; PGD2, prostaglandin D2; RANTES, regulated on activation, normal T cell expressed and secreted;
SNP, single nucleotide polymorphism; UTR, untranslated region.
Kim et al., 2005) and chemokine [C-C motif] receptor 5 (CCR5)
receptors (Hall et al., 1999; Srivastava et al., 2003; Agrawal and
Bharadwaj, 2005).
LEUKOTRIENE MODIFIER (LTM)
PHARMACOGENETICS
The cysteinyl leukotriene ligands (CysLT), including leukotriene
C4 (LTC4), D4 (LTD4) and E4 (LTE4), are powerful
bronchoconstrictors and pro-inflammatory mediators of
atopic asthma (Samuelsson, 1983; Bisgaard, 2001). They are
released by mast cells and macrophages during asthma attacks
(Severien et al., 2000). The severity of an asthma attack can
be influenced by the cellular concentrations of these CysLTs
(Maekawa et al., 2002). These ligands regulate human airway
contractions upon binding to the CysLT receptors (Metters,
1995; Takasaki et al., 2000; Figueroa et al., 2001; Kormann et al.,
2005).
Polymorphic variability is found within many of the genes
involved with the synthesis and signaling pathways of CysLTs.
The influence of these variations to CysLT biosynthesis enzyme
activity, CysLT signaling and asthma severity will be reviewed
below. It is important, however, to distinguish between the effect
of functional variants of risk alleles for atopy or asthma from
pharmacogenetic variants that primarily influence the absorption
or response to LTMs. Pharmacogenetic variants which also confer
susceptibility to disease will be discussed in Section “Cysteinyl
Leukotriene Receptor Polymorphisms.”
Many loci implicated in LTM pharmacogenetics, however,
encode genes that are independent of CysLT-related pathways.
For example, rs12422149, a common c.935G > A polymorphism
in the Solute Carrier organic anion transporting polypeptide
(OATP) 2B1 (SLCO2B1) was associated with absorption of and
response to montelukast in humans. In particular, in vitro studies
have shown that citrus juice may reduce the permeability of
montelukast. Moreover, pharmacokinetic studies of montelukast
co-ingested with citrus juice suggest that co-ingestion resulted
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TABLE 2 | CYSLTR1 receptor variants: naturally occurring polymorphisms and in vitro engineered mutants.
Variant, SNP or
access code)
Type SNP access code Disease association Reference
c.-945T/C
c.-786C/A
c.-647G/A
Promotor
Promotor
Promotor
rs321029
rs2637204
rs2806489
Associated with IgE /atopy
Aspirin intolerant asthma (AIA) associated
Not associated with IgE; Associated with atopy
in females
Kim et al., 2007
Zhang et al., 2006
Duroudier et al., 2009
Kim et al., 2006
TCG (above)
c.-566C/T
c. 927T/C
Haplotype
Promotor
synonymous
Various haploblock
rs7066737
rs320995
Upregulating haplotype not associated
Not associated
Not associated
Associated with asthma
Not associated with atopic asthma
Atopy severity in females
Not associated
Zhang et al., 2006
Duroudier et al., 2009
Choi et al., 2004
Sanz et al., 2006
Kadry et al., 2014
Arriba-Mendez et al., 2006
Hao et al., 2006
Al-Shemari et al., 2008
c.898 G/A C-terminus 300Ser is a hypermorphic variant;
Increased Ca2+ flux
Thompson et al., 2007
Normal expression and desensitization
Increased LTD4 binding;
Increased Inositol Phosphate
Yaddaden et al., 2016
aa, amino acid; IC, intracellular loop; SNP, single nucleotide polymorphism; TM, transmebrane helix. Approximate allele frequency as reported by the Exome Aggregation
Consortium (ExAC), Cambridge, MA, USA (http://exac.broadinstitute.org).
TABLE 3 | CYSLTR2 receptor variants: naturally occurring polymorphisms and in vitro engineered mutants.
Nucleotide position Type SNP access code Disease association Reference
g.-1220A/C
c.-819 T > G
c.2078 C > T
c.2534A > G
c.3105 A/G (Exon1-UTR)
c.-2534A > G
c.601 A/G
Promotor
Haplotype
Haplotype
Coding
rs1323552
rs912278
rs41347648
Associated with asthma
Aspirin intolerant asthma
Stronger association with LTC4S c.-444A > C
Not associated with atopic dermatitis
Not associated
201Ser is associated with atopic asthma
201Ser is a hypomorphic variant; decreased Ca2+ flux
Common allele associated with protection against atopy
Associated with atopy; Hypomorphic
201Ser is hypomorphic
Decreased LTD4 binding
Decreased inositol phosphate production
Fukai et al., 2004
Park et al., 2005
Kato et al., 2011
Kumar et al., 2012
Thompson et al., 2003
Thompson et al., 2006
Pillai et al., 2004
Brochu-Bourque et al., 2011
aa, amino acid; IC, intracellular loop; SNP, single nucleotide polymorphism; TM, transmebrane helix. Approximate allele frequency as reported by the Exome Aggregation
Consortium (ExAC), Cambridge, MA, USA (http://exac.broadinstitute.org).
in genotype specific alterations in absorption. For example, A/G
heterozygotes were demonstrated to have reduced absorption
relative to G/G homozygotes, independent of treatment or
combined treatments (Mougey et al., 2011).
Increasingly, loci of pharmacogenetics significance have been
identified by GWAS. These data underscore the fact that many
loci that alter the efficacy of LTMs pharmaceuticals are not
directly part of the CysLT pathway. Seminal studies by Dahlin
et al. examined patient response to montelukast and the 5-
LO inhibitor zileuton, over 8 weeks and (Dahlin et al., 2015)
and 12 weeks (Dahlin et al., 2016), respectively, using DNA
and phenotypic information from 526 and 217 people enrolled
in placebo-controlled trials. This group based their initial
analysis on the genome-wide genotype and phenotypic data from
American Lung Association’s Asthma Clinical Research Center
(ALA-ACRC) cohorts. These results showed that while rs6475448
[located in the myeloid/lymphoid or mixed-lineage leukemia
(MLLT3) gene] was associated with improved montelukast
response over an 8-week treatment period (Dahlin et al., 2015),
rs12436663 [located in the Mitochondrial Ribonuclease P Protein
3 Precursor (MRPP3) gene, encoding a protein critical to the
cleavage of tRNA molecules], was associated with worsened
zileuton response over a 12-week period (Dahlin et al., 2016). In
both studies, the change in Forced Expiratory Volume (1FEV)
from baseline in response to drug was used as a measure of
treatment response (Dahlin et al., 2015, 2016). Furthermore, the
gene-environment (G × E) GWAS model evaluated in the 12-
week study identified an association between rs517020 (located
in the glycosyltransferase 1 domain containing 1 (GLT1D1) gene)
with worsening responses to both montelukast and zileuton
(Dahlin et al., 2016). These findings implicate loci in LTM
response that, by contrast with leukotriene candidate genes, are
not intuitively related to LTM therapeutic responsiveness (Dahlin
et al., 2015, 2016).
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Next, we will review the polymorphisms in the genes
encoding portions of the CysLT pathway implicated in asthma
pathogenesis and treatment (Figure 1) before discussing the
receptor polymorphisms per se.
LEUKOTRIENE SYNTHESIS
Leukotrienes are fatty acid-derived mediators which are divided
in two main biologically active subgroups, LTB4 and the
cysteine-conjugated leukotrienes (LTC4, LTD4, and LTE4).
The arachidonate 5-lipoxygenase (ALOX5) is required for the
synthesis of the unstable epoxide precursor LTA4 (Figure 1), on
which acts the leukotriene A4 hydrolase (LTA4H) to originate
the proinflammatory chemoattractant LTB4 or the leukotriene
C4 synthase (LTC4S) to conjugate the tripeptide glutathione and
form LTC4; LTD4 and LTE4 are then formed by subsequent
removal of the terminal amino acid of the tripeptide. The
genes which encode for the leukotriene synthesis enzymes all
have polymorphisms that have been investigated in asthma
endophenotypes (Capra et al., 2007; Tantisira and Drazen, 2009).
ALOX5 Polymorphism
The polymorphic region of the ALOX5 gene contains a
functionally important variable number tandem repeat (VNTR)
sequence (rs59439148). The VNTR of the SP1-binding motif of
the ALOX5 promoter (In et al., 1997) is likely to determine the
expression levels of ALOX5 (In et al., 1997; Silverman et al.,
1998). An early study found that patients with no wild type
(WT) allele at the ALOX5 promoter locus have a diminished
response to treatment with the 5-LO inhibitor, ABT-761, which
targets ALOX5 (Drazen et al., 1999b). Though this polymorphism
may not predict asthma risk (Sayers et al., 2003), it may be a
significant determinant of the leukotriene burden associated with
bronchoconstriction (Holgate et al., 1996; Drazen et al., 1999a).
More recently, ALOX5 polymorphisms have been associated with
increased cysteinyl leukotriene production as well as reduced
lung function in children with poorly controlled asthma (Mougey
et al., 2013). In this study, 270 children, 6- to 17-years old, with
poorly controlled asthma were enrolled in a 6-month clinical
trial. A smaller cohort of 137 patients was examined in order
to test the association of the ALOX5 promoter with asthma
outcomes using both additive and recessive genetic models.
Mougey et al. reported that between 14.8% (40/270) and 28%
(38/135) of African Americans were homozygous for variant
alleles of rs59439148. These results suggest that the ALOX5
promoter contributes to increased urinary LTE4 levels, reduced
lung function and potentially worse asthma control. ALOX5
promoter variants may, therefore, be a risk factor for worse
asthma outcomes.
The ALOX5 variants that confer susceptibility to asthma,
therefore, may be of pharmacogenetic significance if an
inadequate quantity of ALOX5 protein is available as a drug
target (Lima et al., 2006; Telleria et al., 2008; Tantisira et al.,
2009). Evidence that g.20C > T (rs4987105) and g.213411G > A
(rs4986832) are associated with improved forced expiratory
volume (FEV1) in response to montelukast, suggests the clinical
relevance of the ALOX5 polymorphisms (Klotsman et al., 2007).
These studies suggest that the 15% or so of individuals who carry
these SNPs may have a heightened response to montelukast that
reflects their endogenously excessive levels of CysLTs.
LTC4S Polymorphism
There is evidence that the gene encoding LTC4S, the enzyme
that adducts glutathione at the C-6 position of the arachidonic
acid backbone (Lam and Austen, 2000), is also polymorphic. The
promoter of the LTC4S gene contains a -444A > C SNP which is
transcriptionally active. However, the activity of this polymorphic
promoter is reported to cause alterations in CysLT production
which are associated with severe asthma (Sampson et al., 2000;
Kedda et al., 2004). This relationship has been confirmed by
meta-analysis (Zhang et al., 2012).
The variant may be of pharmacogenetic significance. Subjects
who were homozygous for the WT LTC4S -444A allele had a
lower response to the CYSLTR1 antagonist zafirlukast, compared
with CC or CA genotypes (Sampson et al., 2000). Two
recent studies report the profound physiological and functional
significance of this polymorphism. The first study found that,
compared with corn oil, a combination of borage and echium
seed oils may improve airflow obstruction in mild to moderate
asthmatics who carry the variant allele in the LTC4S gene (A-
444C; Kazani et al., 2014). The second group that investigated
urinary leukotrienes reported that leukotriene E4 levels may
be higher in patients with the LTC4 synthase -444 A/C
polymorphism (Kadry et al., 2014).
The efficacy of LTMs such as Montelukast are influenced
my many polymorphisms in addition to -444A/C LTC4
polymorphisms. For example, the -441T/C polymorphism of
the prostaglandin D2 receptor (PTGDR) gene is associated
with treatment responsiveness to montelukast. In particular,
when LTA release was examined by exercise challenge in
100 asthmatic children prescribed 5 mg/kg Montelukast,
it was found that minor alleles of the PTGDR -441T/C
and LTC4S -444A/C polymorphisms were associated with
eosinophil count in atopic asthmatic children. While the
LTC4S -444A/C and PTGDR -441T/C were not associated
with the susceptibility for asthma, there was a significant
association between responsiveness to montelukast and the
PTGDR polymorphism. These pharmacogenetic data suggest that
therapies that target the PTGDR may be useful for modulating the
responsiveness to LTRAs (Kang et al., 2011).
These observations suggest that the genes encoding the CysLT
pathway (Figure 1), may contribute additively or synergistically
to altered drug responses or asthma endophenotypes. This
phenomenon was previously suggested by Park et al. (2005).
This group reported that the LTC4S -444A > C [c.-444A > C]
gene polymorphism, in conjunction with the rare c.-819T > G,
c.2078C > T or c.2534A > G alleles of the CYSLTR1 gene, was
associated with aspirin intolerant asthma (Park et al., 2005). Al-
Shemari et al. (2008) initially showed that SNPs of the ALOX5,
CYSLTR1, and ALOX5 genes were found to be associated with
allergic rhinosinusitis. However, the association was diminished
upon correction for multiple testing. This may have resulted
because the study lacked the power to detect polymorphisms
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conferring a relative risk of 2.0 or less to the phenotype:
reflecting the fact that individual risk factors for complex
disease can be quite small (Al-Shemari et al., 2008). However,
while an association of the LTC4S -1072G/A, rs377694, and
rs730012A/C haplotype with asthma was reported, no evidence
of an interaction with the CYSLTR1 gene was identified (Kumar
et al., 2012).
Study of genetic variability in the genes conferring response to
LTMs, including those encoding the CysLT pathway (Figure 1),
therefore, should be subjected to GWAS analysis since this
method is well-suited to assessing the addictive or multiplicative
contribution of genes complex traits.
CYSTEINYL LEUKOTRIENE RECEPTOR
POLYMORPHISMS
There are two distinct genes which encode the two CysLT
receptors: the cysteinyl leukotriene 1 (CYSLTR1) and 2
(CYSLTR2) receptors genes. These two receptor proteins exhibit
variable tissue expression, however, both are expressed in lung
macrophages and in airway smooth muscle (ASM; Metters, 1995;
Lynch et al., 1999; Heise et al., 2000; Takasaki et al., 2000; Figueroa
et al., 2001; Mita et al., 2001). Knock-out mouse studies have
given insight into the pathobiology mediated by the CysLTs
(Kanaoka et al., 2001). CYSLTR2 was revealed to have a major
role in chronic inflammation associated with fibrosis (Beller
et al., 2004a). By contrast, CYSLTR1 was found to be associated
with acute constriction of smooth muscle and anti-inflammatory
counteraction of chronic injury (Beller et al., 2004b). Biochemical
studies have also shown that these two receptors are functionally
distinct. Although, CYSLTR1 has its highest affinity for LTD4
(Lynch et al., 1999; Woszczek et al., 2005), CYSLTR2 binds LTC4
and LTD4 with equal affinity (Heise et al., 2000; Maekawa et al.,
2001); a phenomenon that may define the specificity of the acute
and chronic activity of the CysLTs.
As with other GPCR genes, variants of the cysteinyl
leukotriene receptors (CysLT) include single nucleotide
polymorphisms and insertion or deletions that alter GPCR
expression or function (Balasubramanian et al., 2005). Early
evidence of the possible significance of CysLT receptor variability
was observed in mice: in which the CYSLTR1 transcript has been
shown to undergo alternative splicing that alters the function of
the protein (Maekawa et al., 2001). From 2001 to the present,
a number of groups have been investigating the contribution
of variability of the two CysLT receptors to atopic asthma and
response to pharmacological interventions. Selected CysLT
receptor polymorphisms are presented in Tables 2 and 3.
Human polymorphisms, including coding variants as well
as has functional promotor haplotypes that either increase or
decrease the expression of either receptor are presented in
Tables 2 and 3. The epidemiology and in vitro studies discussed
below suggest that functional receptor variants are associated
with asthma endophenotypes and altered pharmacological
response once environmental factors such as smoking were
controlled for (Thompson et al., 2014a). The disturbances
include the alteration of: ligand binding; G-protein coupling;
dimerization; desensitization; receptor trafficking to the cell
surface as well as receptor mRNA expression (Rana et al., 2001;
Thompson et al., 2014a).
Early studies of the effect of amino acid substitutions in
the CYSLTR1 and CYSLTR2 receptor genes in atopic asthma
were based on a personalized medicine hypothesis (Thompson
et al., 2005a, 2006, 2014b; Capra et al., 2007). The LTM class of
drugs has been found to be ineffective in greater than 20% of
patients (Noonan et al., 1998). We originally hypothesized that
genetic polymorphisms influenced the efficacy of drugs that act
at the CYSLTR1 receptor, such as the high-affinity antagonist
ligands (e.g., montelukast, pranlukast, zafirlukast; Reiss et al.,
1996; Grossman et al., 1997; Suissa et al., 1997; Obase et al., 2001).
Further, we proposed that even though the CYSLTR2 receptor is
not a current drug target, knowledge of the polymorphisms of
this potential drug target maybe clinically valuable to refractory
patients in the future.
We discuss these findings in the context of the body
of cysteinyl leukotriene receptor pharmacogenetics that has
since been established. Selected CYSLTR1 and CYSLTR2
polymorphisms are presented in Tables 2 and 3.
Cysteinyl Leukotriene 2 Receptor
Polymorphisms
Four independent groups (Thompson et al., 2003, 2013) have
identified significant associations between the CYSLTR2 gene loci
and atopy (Fukai et al., 2004; Pillai et al., 2004; Park et al., 2005;
Thompson et al., 2013). The amino acid alignment (Figure 2)
shows the location of CYSLTR2 variant with respect to the
transmembrane (TM) domains. The CYSLTR2 receptor is shown
schematically in Figure 3.
The 610 A > G variant which encodes the Met201Val
CYSLTR2 receptor variant was originally identified in the Tristan
da Cunha population has also been reported by Pillai et al.
(2004). A less remarkable Ser236Leu variant, which was originally
identified in the Tristan population (Thompson et al., 2003),
may be present in as many as 10% of persons of African
descent according to the Exome Aggregation Consortium,
ExAC1. Though the Ser236Leu variant has not been examined
in asthmatics of African origin, it has been seen compounded
with Met201Val. This may be important for Tristanian asthmatics
identified to be compound heterozygous for the Met201Val and
Ser236Leu variants of CYSLTR2.
The Met201Val variant that was found to be associated with
atopic asthma on Tristan da Cunha (Table 3) has subsequently
been reported to have frequency of between 2.6% in the general
population according to the Exome Aggregation Consortium
(ExAc)1. The essentially inactivating character of the Met201Val
the polymorphism (Thompson et al., 2003), to be discussed
in below, has been confirmed by the group of Pillai et al.
(2004) Their data show that Met201Val is associated with asthma
phenotypes in a large population genetics study. Definitive
studies using SNPs that saturate CYSLTR2 may be necessary
before these findings are placed in context, however, since
association studies with non-coding SNPs or haplotypes built
1http://exac.broadinstitute.org
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FIGURE 2 | Alignment of the protein structure of the cysteinyl leukotriene 1 (CYSLTR1 ) and 2 (CYSLTR2) receptors in relation to rhodopsin. The amino
acids conserved between these family A receptors are shown. The consensus is greater than 50%. These data formed the basis of the model predicting the
CYSLTR1 and CYSLTR2 transmembrane domains (helices 1–7), the four β-sheets, and the putative cysteinyl leukotriene-binding domain. The amino acid variants
that are associated with atopy or asthma, the G300S CYSLTR1variant, and the M201V CYSLTR2 variant are each boxed and noted with arrows (adapted from
Thompson et al., 2014a).
from only a few SNPs (Kato et al., 2011; Kumar et al., 2012) are
unlikely to be definitive.
Cysteinyl Leukotriene 1 Receptor
Variants
The presence of SNPs in both the CYSLTR1 and CYSLTR2
genes may increase the risk for atopic asthma (Tables 2 and
3). Since the CYSLTR1is the target for anti-asthma drugs
such as montelukast, the CYSLTR1 SNPs may provide an
opportunity to examine the amino acid residues necessary
to the structure-activity relationships that define drug action.
The CYSLTR1 gene, located at Xq13-21.1, has been examined
in atopic asthma (Table 2). CYSLTR1 variants, such as the
927 T > C variant (rs320995), have been associated with
asthma (Hong et al., 2009) in out-bred populations. While
this SNP was also noted in the Tristan da Cunha population
(Thompson et al., 2013), it has not been replicated in all
studies of atopic asthma (Kadry et al., 2014). A nucleotide
substitution at 898G > A resulting, in vitro, in a functional
Gly300Ser substitution (Thompson et al., 2007) is discussed
below.
Taken together, many studies suggest that transcriptionally
active CYSLTR1 variants influence the onset and severity of
asthma associated endophenotypes such as atopy (Sokolowska
et al., 2009). The significance of CYSLTR1 variants can be
interpreted in the context of a large study of asthmatics born in
Great Britain during 1958. This study, however, did not identify
coding variants associated with atopy or asthma (Duroudier et al.,
2009). Among those variants examined in vitro, only the 206Ser
variant has been found by the Exome Aggregation Consortium1.
Our ongoing GWAS study of Tristan da Cunha will ultimately
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FIGURE 3 | Structure of the cysteinyl leukotriene 2 (CYSLTR2)
receptor and variants. The positions of the transmembrane (TM)-spanning
domains of the CysLT receptor, the putative binding pocket, and the
Met201Val amino acid substitution are shown in relation to the cutaway
plasma membrane.
resolve the questions raised by the pioneering work we undertook
in this population.
Co-inheritance of CYSLTR1 and
CYSLTR2 Variants
We can hypothesize that epistasis involving inheritance of
variants of both receptors contributes to the phenotype. The
putative co-inheritance of CYSLTR1 and CYSLTR2 variants
suggest a mode of asthma inheritance that is the result of epistasis.
Proof of principal may be found in data showing that variants
of two genes encoding other GPCR pathway proteins appear to
be implicated in asthma pathogenesis. For example, it is likely
that an interaction between variant forms of NPSR1 with variants
of the retinoid receptor-related orphan receptor alpha (RORA)
nuclear repressor gene may contribute to a variety of asthma
phenotypes (Acevedo et al., 2013). Similarly, the contribution
of CYSLTR1 and CYSLTR2 alleles may contribute additively or
synergistically to asthma in association with other risk alleles and
environmental factors.
PHARMACOLOGY OF CYSLTR1 AND
CYSLTR2 RECEPTOR VARIANTS
The associations of the CYSLTR1 and CYSLTR2 genes with atopy
and asthma provided the rationale for studying the functional
consequences of these variants with respect to agonist and their
possible contribution to the atopy phenotype (Thompson et al.,
2003, 2007, 2013). By contrast, a putative high affinity LTE4
receptor (Kanaoka et al., 2013), GPR99 (also known as an
oxoglutarate receptor) may not be involved since the actions of
LTD4 can account for the phenotype at the cognate CYSLTR1
and CYSLTR2 receptors. The CysLT receptor CYSLTR2 variants
are discussed in the context of their potential to influence LTM
response.
Functional Variants of CYSLTR2
The 601 A > G variant that is associated with atopic asthma in
both the Tristan da Cunha (Thompson et al., 2003) and European
populations (Pillai et al., 2004) encodes the Met201Val variant of
transmembrane domain five (TMD5; Figure 3). GPCR models
suggest this variant creates a mildly deleterious hypomorphic
protein (Bromberg and Rost, 2007; Kazius et al., 2008; Bromberg
et al., 2009; Vroling et al., 2011; Rana et al., 2012; Thompson
et al., 2014a). Our work has recently confirmed the variant to
be hypomorphic (Brochu-Bourque et al., 2011). The CYSLTR2
inactivating mutation results in reduced ligand binding, Ca2+
flux (Figures 4D and 5B) and inositol phosphate (IP) generation
(Figure 6; Thompson et al., 2003; Pillai et al., 2004; Brochu-
Bourque et al., 2011).
In general, the effects of Met201Val were more pronounced
with respect to LTD4 compared with LTC4. This effect
is compounded by deficits in ligand binding that were
again more significant for LTD4 than LTC4 (Figure 4). The
fact that LTD4 release is more commonly associated with
asthma severity, may explain why this variant is clinically
relevant. The fact that the CYSLTR2 variant is both relatively
common and associated with asthma in out-bred populations
suggests that the variant is of relevance to the general
population.
Functional Variants of CYSLTR1
Since the CYSLTR1 Gly300Ser variant has not been reported
in the general population, our functional analysis of the
Gly300Ser variant will be especially informative if the
CYSLTR1 gene is implicated in disease pathogenesis. Our
in vitro study of the Gly300Ser variant (Figures 7 and 8;
Yaddaden et al., 2016) provided among the first structural
insights into CysLT receptors using site directed mutagenesis.
This represents a significant advance in understanding the
relatively under-studied GPCR receptors for the cysteinyl
leukotrienes.
When the engineered Gly300Ser variant receptor was
expressed it in COS-7 cells, the variant was more sensitive to
the LTD4 agonist (Figures 7 and 8). Binding properties of the
variant (measured by Bmax and Kd) indicates that the CYSLTR1
variant has higher affinity for ligand than the WT (Figure 7)
by comparison with the CYSLTR2 polymorphism that has less
affinity for ligand than the WT (Figure 4). By contrast, the
CYSLTR1 206Ser variant, originally identified in the Tristan da
Cunha population, and later found at low frequencies in atopics,
asthmatics and control subjects throughout the world, was not
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FIGURE 4 | Radioligand binding studies of LTC4 or LTD4 with CYSLTR2 WT or CYSLTR2 Met201Val cells. (A,B) Saturation binding isotherms for [3H]LTC4
to CYSLTR2 WT (A) or CYSLTR2 Met201Val (B). Radioligand binding assay was performed with increasing amounts of [3H]LTC4 (0.1–12 nM) in the presence or
absence of unlabeled ligand. (C,D) Saturation binding isotherms for [3H]LTD4 to CYSLTR2 WT (C) or CYSLTR2 Met201Val (D). Radioligand binding assay was
performed with increasing amounts of [3H]LTD4 (0.1–15 nM) in the presence or absence of unlabeled ligand. The calculated specific binding was analyzed by
non-linear transformation using Prism (Graph Pad Software, Inc.) to generate Kd and Bmax values. Saturation curves are representative of four independent
experiments. Insets: Scatchard representation of the specific binding isotherm (adapted from Brochu-Bourque et al., 2011).
found to be functional (Thompson et al., 2007; Yaddaden et al.,
2016).
In fact, while ligand binding (Figure 7), IP generation
(Figure 8) and Ca2+ flux (Figure 5A) was reduced compared
to CYSLTR1 WT, the expression of the CYSLTR1 Gly300Ser
variant receptors (Figure 9) and their desensitization in response
to agonist was found to be normal (Thompson et al., 2007).
These data suggest that CYSLTR1 CYSLTR1 antagonists, such
as montelukast, may correct a putative elevation in CYSLTR1
signaling in atopic asthma.
The relative location of variants of the receptors is shown
in an alignment of each CysLT receptor (Figure 2) that was
constructed with respect to the transmembrane-spanning and
the putative binding pocket of the receptors. The data suggests
that the putative CysLT binding site is partially determined
by the integrity of the transmembrane domains. The abnormal
but opposite pharmacology of variants of the receptors, causing
increased potency of LTD4 at the Gly300Ser CYSLTR1 receptor
variant (located in the intracellular portion of TMD7) and
decreased potency of LTD4 at the Met201Val CYSLTR2 receptor
variant (located in the extracellular portion of TMD5) contributes
important in vitro data on the structural significance of the
specific amino acid residues in these GPCRs.
Putative Interaction between the
CYSLTR1 and CYSLTR2 Receptors
It has been proposed that macrophages and eosinophils attenuate
the strength of CysLT-mediated signaling by limiting the
formation of CYSLTR1 receptor homodimers and/or controlling
their surface expression. With respect to MAP Kinase signals,
it seems possible that WT CYSLTR2 receptors interact with
WT CYSLTR1 receptors to inhibit functional responses of
WT CYSLTR1 receptors. In mast cells, ligand activation
of the WT CYSLTR2 receptor results in reduced signaling
from ligand activated CYSLTR1 WT receptors. Although, the
CYSLTR1 and CYSLTR2 receptor interaction is best modeled
with respect to mitogenic signals (Jiang et al., 2007), it is
possible that more rapid processes such as IP generation
or calcium flux may be analogous. We hypothesize that
a CYSLTR1/CYSLTR2 “counterbalance” may regulate CysLT-
dependent functions in immune and inflammatory responses.
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FIGURE 5 | Summary of the in vitro effects of Gly300Ser cysteinyl
leukotriene 1 (CYSLTR1) receptor and Met201Val on CYSLTR2
receptor signaling compared with wild type (WT). (A) Cysteinyl
leukotriene D (LTD) concentration-response curve for CysLT receptors in
transfected cells. Inositol triphosphate (InsP) generation assay of the variants
and WT forms of the CYSLTR1 receptor. both 300Ser and 206Ser variants’
EC50 were significantly different from WT. The concentrations of LTD required
to produce the InsP effect were much higher than those used in the [Ca2+]
assay shown in (B), in which calcium flux was assayed for the variants and
WT and variant forms of the CYSLTR1 receptor challenged with LTD. The
resulting changes in intracellular calcium concentrations were measured as
fluorescence maximum. For LTD4, the Met201Val variant (#) had a
significantly greater EC50 compared to WT (), while the Ser236Leu(1) and
Ala293Gly/Arg316Lys ( R©) variants were not different. However, the
Ala293Gly/Arg316Lys variant showed decreased efficacy (V; adapted from
Thompson et al., 2014a).
This balance may be disrupted by the Met201Val variant
of CYSLTR2 if the LTD4 dependent signal is necessary to
balance the LTD4 ligand-dependent CYSLTR1 signal. This
effect may be amplified in people who also carry a CYSLTR1
variant.
The CYSLTR2 receptor may be important to the
pharmacology of CYSLTR1 pharmaceuticals if, like many
GPCRs, these receptors form functional heterodimers with
unique pharmacological properties. Co-expression of variant
receptors may alter CysLT signaling. While evidence for
a functional interaction between CYSLTR1 and CYSLTR2
receptors in mast cells seems likely (Jiang et al., 2007), the
functional consequence of putative heterodimers, or other
functional interactions formed between variants, remains to be
fully demonstrated. The fact that deletion of either the CYSLTR1
or CYSLTR2 receptors totally eliminates CysLT-mediated
cutaneous edema (Lynch et al., 1999), however, suggests that a
CYSLTR1/CYSLTR2 interaction may regulate some responses
to CysLT mediators. It may be possible to test the hypothesis that
FIGURE 6 | Effect of CysLTs on IP production by CYSLTR2 WT (black
bars) or CYSLTR2 Met201Val (gray bars) cells. Cells were labeled with
[3H]myo-inositol for 16 h, and then stimulated for 45 min with EtOH and LTC4
(A) or LTD4 (B) at the indicated concentrations before measurement of
radioactivity. Results are presented as cpm of inositol phosphate production.
Data are expressed as mean ± SE of 15 (A) or 9 (B) independent
experiments. Lane C, control using EtOH (100 nM). ∗∗∗p < 0.001, using
two-way ANOVA with Bonferroni post-tests (adapted from Brochu-Bourque
et al., 2011).
CYSLTR2 negatively regulates CYSLTR1 signaling by examining
the signaling consequences of co-expressing CYSLTR1 variants
with the 201Val CYSLTR2 variant.
CONCLUSION
Central to this narrative is a discussion of how variability in
the genes encoding the proteins essential for CysLT signaling
may influence risk for inflammation that is associated with
asthma, cognizant of the fact that variability these genes may
also increase susceptibility to asthma independent of their
potential LTM pharmacogenetic relevance. Asthma susceptibility
loci, which confer risk for the complex respiratory traits
that lead to asthma, and pharmacogenetic loci, which confer
the traits that define the responsiveness of an individual
to pharmaceutical therapy, are presented in the context of
the linkage analysis, candidate gene studies and/or GWAS
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FIGURE 7 | Binding of LTD4 to the CYSLTR1-WT receptor and its
variants in transiently transfected HEK293 cells. Forty-eight hours
post-transfection, 3H-LTD4 was added to the cells for 1 h, in the presence or
absence of non-radioactive LTD4. Following several washes, the radioactivity
was measured in a beta-counter (n = 3). Specific binding was calculated by
subtracting the non-specific binding (in presence of competition from
radioactive LTD4) from the total binding measured (Yaddaden et al., 2016).
FIGURE 8 | Inositol phosphate production in CYSLTR1-transfected
cells. Forty-eight hours post-transfection, cells were stimulated for 30 min
with LTD4 or LTC4 at 0.01–100 nM. IP-1 production was measured using an
antibody against IP-1 and a fluorescent FRET IP-1 conjugate competitor.
(A) IP-1 production by CYSLTR1-transfected HEK-293 cells in response to
LTD4 (B) and to LTC4. Two-way ANOVA analysis; n = 6; ∗p < 0.05,
∗∗p < 0.01, ∗∗∗p < 0.001 (adapted from Yaddaden et al., 2016).
approaches used to identify them. In most cases, these loci can
be modeled as independent complex traits with both genetic and
environmental (GXE) contributions. Therefore, we review the
relative contribution of genes in the CysLT pathway to both the
etiology of asthma itself and a person’s responsiveness to LTM
drugs.
Common genetic variants (e.g., SNPs) typically contribute
effects of as little as 1% to a complex phenotype described
in a given population. As a result, GWAS can be used to
confirm the significance of the cysteinyl leukotriene gene variants
to atopic asthma on Tristan da Cunha. While it is possible
that affected Tristanians may inherit a variety of other genetic
risk factors for atopy and/or asthma, including potential ETS-
2 and ETS-3 variability (Baron et al., 2002; Silverman et al.,
2002; Wu et al., 2008), we present evidence that suggests that
the CYSLTR2 601 A > G variant is associated with atopic
asthma. The contribution of other known atopy variants, such
as those in the DENND1B gene, located on chromosome
1q31 (Sleiman et al., 2010) and the ORMDL3 gene, located
on chromosome 17q12 (Moffatt et al., 2007) to the asthma
phenotype is also possible. Like other asthma susceptibility
loci, the CYSLTR2 601 A > G variant has been shown to
contribute to asthma in large out-bred populations (Pillai et al.,
2004).
While the CYSLTR2 variant was originally identified in 13%
of the Tristan da Cunha population (Thompson et al., 2003) it is
only present in approximately 2.6% in the European population.
In both instances, the variant has been associated with atopic
asthma (Thompson et al., 2003; Pillai et al., 2004). A large study
of CYSLTR1 variants in asthmatics born in Great Britain during
1958 did not identify the 898 G > A variant (Duroudier et al.,
2009) nor is it found in over 60,000 exomes by the Exome
Aggregation Consortium1. The 898 G> A CYSLTR1 is, however,
among the best studied coding variants of a receptor for any LTM
drug.
By contrast with asthma susceptibility loci, in most cases
the pharmacogenetic determinants of drug response represent
a distinct category of risk loci that may not influence disease
onset directly. For example, the pharmacogenetic variability
that influences LTM response can be attributable to genes
that are both integral (Kang et al., 2011; Mougey et al.,
2013; Figure 1), or lie outside (Dahlin et al., 2015, 2016)
CysLT signaling pathways. In this context, CysLT receptor
variants have provided insight into the role of GPCR variants
as genetic risk factors for disease, altered drug response, or
ADRs (see Table 1) and may represent reagents necessary
for refined LTM drug discovery and/or personalized medical
interventions (Spiegel and Weinstein, 2004). The significance
of the CysLT receptor variants to both the development of
asthma and LTM response, however, is best evaluated in the
context of other polymorphisms that influence the phenotype.
For example, the enzymes involved in the formation of the
leukotrienes (Figure 1) often result in variable production of
the CysLTs (LTC4, LTD4, and LTE4) and LTB4. The many
examples discussed include, the VNTR sequences located in the
Sp1-binding motif within the promotor region of the ALOX5
gene that are associated with both LTM response, leukotriene
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FIGURE 9 | Confocal microscopy imaging of cysteinyl-leukotriene 1 (CYSLTR1) WT and variant receptors in transiently transfected cells. Cells were
fixed and immunofluorescently stained with anti-CYSLTR1R antibody (green) followed by Alexa 488 goat anti-rabbit antibody (red) as described under Methods
section. Superimposed images of immunoreactivity of (a) WT CYSLTR1 receptor, (b) Gly300Ser CYSLTR1 receptor variant or (c) Ile206Ser CYSLTR1 receptor
variant, in basal condition. One representative experiment is shown (adapted from Thompson et al., 2007).
burden and bronchoconstriction (Drazen et al., 1999a), and
the 444A > C SNP polymorphism in the LTC4S gene that is
associated with severe asthma, leukotriene burden and altered
response to the CYSLTR1 LTMs (Sampson et al., 2000; Kadry
et al., 2014; Kazani et al., 2014). Genetic variability in CysLT
pathway may contribute additively or synergistically to altered
drug responses.
Since very large GWAS studies are needed to detect
polymorphisms conferring a relative risk of 2.0 or less to the
phenotype (Al-Shemari et al., 2008), results suggesting that
CTSLT1R variants may interact with other polymorphic variants
can be difficult to replicate (Kumar et al., 2012). This may reflect
the fact that LTM targets can be quite diverse. For example, the
fact that PTGDR polymorphism has been significantly associated
with responsiveness to montelukast may confound earlier studies
of LTM pharmacogenetics. Indeed, LTM therapies may be
developed that selectively target the PTGDR since this receptor
may be a useful way to modulate responsiveness to LTRA (Kang
et al., 2011).
Many genes that are associated with altered efficacy of LTMs
pharmaceuticals, however, are not directly part of the CysLT
pathway. For example, variation in the SLCO2B1 gene has
associated with altered absorption of montelukast administered
in the presence of citrus. These data suggest that genetic factors
influence pharmacokinestics of LTM response (Mougey et al.,
2011).
GWAS studies of LTM response in people enrolled in
placebo-controlled trials have also been undertaken. Dahlin
et al. (2015, 2016) examined LTM response using DNA
and phenotypic information from placebo-controlled trials
from the American Lung Association’s Asthma Clinical
Research Center (ALA-ACRC) cohorts. SNPs that both
favored [rs6475448, located in the myeloid/lymphoid or
mixed-lineage leukemia (MLLT3) gene; Dahlin et al., 2015],
or worsened [rs12436663, located in the Mitochondrial
Ribonuclease P Protein 3 Precursor (MRPP3) gene], rs517020
[located in the glycosyltransferase 1 domain containing
1 (GLT1D1) gene] LTM response have been identified
(Dahlin et al., 2016). These findings implicate loci in LTM
response that, by contrast with CysLT receptor genes or
the biosynthesis genes (Figure 1), are not intuitively related
to LTM therapeutic responsiveness (Dahlin et al., 2015,
2016).
As a result, it is necessary that a GWAS approach is used to
confirm the significance of the putative contribution of cysteinyl
leukotriene gene variants to asthma and/or drug response in
the context of other asthma susceptibility genes and genes
that influence LTM pharmacogenetics. This strategy might we
reveal novel genotype–phenotype correlations; as we did for
the melanocortin 1 receptor (MC1R) variants (Beaumont et al.,
2007).
With respect to Tristan da Cunha, this analysis is likely to
identify variety of other genetic risk factors for atopic asthma
and/or LTM drug response. These include loci associated with
asthma in other populations such as the DENND1B gene, located
on chromosome 1q31 (Sleiman et al., 2010). Exclusion of the
ORMDL3 gene, located on chromosome 17q12 (Moffatt et al.,
2007), may also be possible. In addition, loci already implicated
in the Tristan phenotype such as ETS-2 and ETS-3 (Baron
et al., 2002; Silverman et al., 2002; Wu et al., 2008) and the
better documented CYSLTR2, can be evaluated in the context
of those loci, such as CYSLTR1, that may have pharmacogenetic
significance.
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